BECN1 and acute myeloid leukemia: The IκB/NFκB inhibitor BMS-345541 was tested alone and in combination with rapamycin during 4 and 24 hours of culture (AML cells from 9 patients examined), but the drug did not have any statistically significant effect on the overall results neither when tested alone nor in combination with rapamycin on the phosphorylation of the mTOR substrate S6RP, viability/apoptosis, lysosomal acidity, or intracellular protein levels of autophagy-associated (LC3B, Beclin-1, ATG-3, ATG7, ATG-10) and apoptosis-regulating intracellular mediators (bcl-2, bax, bcl-XL) (data not shown).